The incidence of venous thromboembolism (VTE) events in patients with COVID-19 treated
with a standard thromboprophylaxis dose of anticoagulants remains high. We conducted a …

Background: COVID-19 patients are at high thrombotic risk. The safety and efficacy of
different anticoagulation regimens in COVID-19 patients remain unclear. Methods: We …

Background Thromboembolic events are common complications of COVID-19. Clinical study
results on safety and efficacy of anticoagulation in COVID-19 are controversial. Material and …

Coronavirus disease 2019 (COVID‐19) is associated with a hypercoagulable state. It has
been hypothesized that higher‐dose anticoagulation, including therapeutic‐dose and …

Background The incidence of venous thromboembolic events (VTE) in patients with COVID-
19 is generally high but varies markedly. However, the relationship between anticoagulation …

Background: Coagulopathy and thromboembolic events are common in Covid‐19 patients
and are poor prognostic factors. Controversy exists regarding the potential of …

We conducted a systematic review and a meta-analysis to assess the association of
anticoagulants and their dosage with in-hospital all-cause mortality in COVID-19 patients …

A higher risk of thrombosis has been described as a prominent feature of coronavirus
disease 2019 (COVID-19). This systematic review synthesizes current data on thrombosis …

Rising incidence of thromboembolism secondary to COVID-19 has become a global
concern, with several surveys reporting increased mortality rates. Thrombogenic potential of …

Objective We aimed to perform a meta-analysis to summarize the overall evidence from
randomized controlled trials related to higher-intensity anticoagulation in hospitalized …